Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Daily News

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Todd Neale

September 13, 2016

News Daily News

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Caitlin E. Cox

July 07, 2016

News Daily News

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

May 30, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Jason Kahn

March 22, 2012

News Daily News

Drug-Eluting Balloon Continues to Show Positive Results in SFA, Popliteal Disease

Jason Kahn

September 15, 2011

Advertisement

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Drug-Eluting Balloon Continues to Show Positive Results in SFA, Popliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content